The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC - IASLC

The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC – IASLC

IASLC shared a post on X:

Catch the new episode of Lung Cancer Considered as Narjust Florez and Pamela Samson discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC, based on the LAURA trial.

Listen now. 

More episodes.

cancer fight against cancer Global awareness Global fight against cancer IASLC LAURA trial Lung Cancer Considered Narjust Florez NSCLC OncoDaily Oncology osimertinib Pamela Samson